Payload Information
General Information of This Payload
| Payload ID | PAY0TYZLD |
|||||
|---|---|---|---|---|---|---|
| Name | CN115429893A ADC3 Payload |
|||||
| Synonyms |
CN115429893A ADC3 Payload
Click to Show/Hide
|
|||||
| Structure |
|
|||||
| Formula | C26H24FN3O6 |
|||||
| Isosmiles | CC1=C(F)C=C2C3=C1CC[C@H](NC(CO)=O)C3=C(C(C4=CC([C@]5(CC)O)=C6COC5=O)=N2)CN4C6=O |
|||||
| InChI |
InChI=1S/C26H24FN3O6/c1-3-26(35)15-6-19-23-13(8-30(19)24(33)14(15)10-36-25(26)34)22-17(28-20(32)9-31)5-4-12-11(2)16(27)7-18(29-23)21(12)22/h6-7,17,31,35H,3-5,8-10H2,1-2H3,(H,28,32)/t17-,26-/m0/s1
|
|||||
| InChIKey |
PLXLYXLUCNZSAA-QLXKLKPCSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
493.491 |
Polar area |
130.75 |
||
Complexity |
1535.21746 |
xlogp Value |
1.62292 |
|||
Heavy Count |
36 |
Rot Bonds |
3 |
|||
Hbond acc |
8 |
Hbond Donor |
3 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
CN115429893A ADC3 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
63.07%
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
In the SKOV3 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
|
||||
| In Vivo Model | SKOV3 xenograft model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
63.07%
|
Positive HER2 expression (HER2+++/++) | ||
| Method Description |
In the SKOV3 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
|
||||
| In Vivo Model | SKOV3 xenograft model | ||||
CN115429893A ADC6 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
91.30%
|
Positive Trop2 expression (Trop2+++/++) | ||
| Method Description |
In the MX-1 xenograft model, the ADCs were administered at 2.5 mg/kg (once, IV).
|
||||
| In Vivo Model | MX-1 xenograft model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
91.30%
|
Positive Trop2 expression (Trop2+++/++) | ||
| Method Description |
In the MX-1 xenograft model, the ADCs were administered at 2.5 mg/kg (once, IV).
|
||||
| In Vivo Model | MX-1 xenograft model | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
101.70%
|
Positive Trop2 expression (Trop2+++/++) | ||
| Method Description |
In the Capan-1 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
|
||||
| In Vivo Model | Capan-1 xenograft model | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
101.70%
|
Positive Trop2 expression (Trop2+++/++) | ||
| Method Description |
In the Capan-1 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
|
||||
| In Vivo Model | Capan-1 xenograft model | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
108.84%
|
Positive Trop2 expression (Trop2+++/++) | ||
| Method Description |
In the MX-1 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
|
||||
| In Vivo Model | MX-1 xenograft model | ||||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
108.84%
|
Positive Trop2 expression (Trop2+++/++) | ||
| Method Description |
In the MX-1 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
|
||||
| In Vivo Model | MX-1 xenograft model | ||||